Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

This study is currently recruiting participants.

Study NCT00274742 Information provided by Micromet AG

First Received: January 10, 2006 Last Updated: August 11, 2009 History of Changes

No Study Results Posted for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	May 2010
Estimated Primary Completion Date:	No date given